Congress funds biosecurity standards for synthetic DNA manufacturing

What it does

This bill amends the Research and Development, Competition, and Innovation Act to direct the National Institute of Standards and Technology (NIST) to develop best practices, technical standards, and screening tools for biosecurity risks in nucleic acid synthesis (DNA/RNA manufacturing). It requires NIST to convene a consortium of industry, universities, nonprofits, and customers to establish screening standards and report findings within 18 months, and authorizes $5 million annually from 2027–2031 for this work.

Why we flagged it

The bill's operative mechanism is research funding and standard-setting for nucleic acid synthesis screening—a technical biosecurity measure. It is not a subsidy, deregulation, or carve-out, but rather a government investment in public-health infrastructure and industry coordination.

What the text implies

• The consortium structure gives synthetic biology and biomanufacturing companies a formal seat at the table in setting federal biosecurity standards—potentially allowing industry to shape screening thresholds and compliance costs in their favor.
• The bill does not establish enforcement mechanisms or penalties for non-compliance with the standards developed; it is purely advisory and research-focused, limiting its practical impact on actual screening practices.
• Artificial intelligence is explicitly mentioned as a risk factor in engineering biology, but the bill does not specify how AI-related biosecurity risks will be addressed or who will oversee AI-assisted synthesis screening.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill funds research and standard-setting to reduce biosecurity risks from synthetic nucleic acid synthesis—a dual-use technology that could be misused for bioweapons or pathogens. Ordinary citizens benefit from stronger screening and security practices that reduce the risk of engineered biological threats. The consortium structure includes public stakeholders (nonprofits, universities) alongside industry, creating transparency and shared responsibility.

Who stands to gain

• synthetic biology and biomanufacturing companies (industry consortium participation, standardized co
• National Institute of Standards and Technology (research funding)
• universities and research institutions (consortium participation, potential research contracts)

Named in the bill

National Institute of Standards and Technology (NIST), Research and Development, Competition, and Innovation Act, Section 10221, synthetic nucleic acid synthesis, engineering biology, biomanufacturing, biosecurity, House Committee on Science, Space, and Technology, Senate Committee on Commerce, Science, and Transportation

Where it stands

3 cosponsors: 2 Democrats, 1 Republicans.

• Apr 28, 2025 — Introduced · Congress.gov: “Introduced in House”
• Apr 28, 2025 — Referred to House Committee on Science, Space, and Technology and Senate Committee on Commerce, Science, and Transportation · Congress.gov: “Referred to the House Committee on Science, Space, and Technology”
• Apr 29, 2025 — Markup held in committee · Congress.gov: “Committee Consideration and Mark-up Session Held”
• Apr 29, 2025 — Reported out of committee · Congress.gov: “Ordered to be Reported by Voice Vote”
• Jul 20, 2026 — Passed the House · Congress.gov: “On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4666)”
• Jul 20, 2026 — Floor vote scheduled · Congress.gov: “Mr. Babin moved to suspend the rules and pass the bill, as amended”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.